0 331

Cited 11 times in

INTRAVITREAL RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND THE RISK OF STROKE: A National Sample Cohort Study

Authors
 Rim, Tyler Hyungtaek  ;  Lee, Christopher Seungkyu  ;  Lee, Sung Chul  ;  Kim, Do wook  ;  Kim, Sung Soo 
Citation
 RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, Vol.36(11) : 2166-2174, 2016 
Journal Title
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
ISSN
 0275-004X 
Issue Date
2016
MeSH
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/therapeutic use* ; Choroidal Neovascularization/drug therapy* ; Cohort Studies ; Databases, Factual ; Female ; Humans ; Incidence ; Intravitreal Injections ; Male ; Middle Aged ; Ranibizumab/therapeutic use* ; Republic of Korea/epidemiology ; Risk Factors ; Stroke/epidemiology* ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity ; Wet Macular Degeneration/drug therapy*
Abstract
PURPOSE: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration.

METHODS: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n = 467). The two types of comparison groups were defined as comorbidity-matched controls (n = 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n = 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used.

RESULTS: Stroke occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbidity-matched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio = 0.88; 95% confidence interval, 0.60-1.30; hazard ratio = 0.95, 95% confidence interval, 0.64-1.41, respectively).

CONCLUSION: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006982-201611000-00017&LSLINK=80&D=ovft
DOI
10.1097/IAE.0000000000001084
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Wook(김도욱)
Kim, Sung Soo(김성수) ORCID logo https://orcid.org/0000-0002-0574-7993
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
Rim, Tyler Hyungtaek(임형택)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152795
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links